Stay updated on Nivolumab for High-Risk Prostate Cancer Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.

Latest updates to the Nivolumab for High-Risk Prostate Cancer Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check17 days agoChange DetectedThe webpage has removed detailed information about a Phase II clinical trial for nivolumab as a treatment for prostate cancer, including specific eligibility criteria and study procedures, while adding references to collaborators and a new version revision.SummaryDifference39%
- Check24 days agoNo Change Detected
- Check31 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check74 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference2%
- Check89 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check96 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
Stay in the know with updates to Nivolumab for High-Risk Prostate Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk Prostate Cancer Clinical Trial page.